Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250011/S002

ProVee System for BPH

Proverum, Ltd. · Decision date Jun 3, 2026

FDA DECISIONP250011/S002

What did the FDA decide?

FDA records P250011/S002 as a supplement to PMA P250011, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 3, 2026.

FDA approval order statement

to increase the routine bioburden sampling size from 3 to 5 units per sampling period
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Jun 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P250011/S002
Regulatory pathway
PMA supplement
Product code
MER
Decision code
OK30
Decision date
Jun 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.

Product code
MER
FDA device class
3

For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250011 · Original PMA

    ProVee System for BPH

  2. P250011/S002 received

    Application receipt date recorded by FDA.

  3. P250011/S002 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250011

Product / regulatory recordCompanyPathwayDecision dateSource
Proverum, Ltd.PMA approvalDec 9, 2025FDA
Proverum, Ltd.PMA supplementMar 19, 2026FDA
Proverum, Ltd.PMA supplementJun 15, 2026FDA
Proverum, Ltd.PMA supplementJul 1, 2026FDA
Proverum, Ltd.PMA supplementSep 24, 2026FDA
Proverum, Ltd.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Other records with product code MER

Product / regulatory recordCompanyPathwayDecision dateSource
Zenflow, Inc.PMA approvalDec 11, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Proverum, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records